Enlivex Therapeutics (NASDAQ:ENLV) Upgraded at Wall Street Zen
by Mitch Edgeman · The Markets DailyWall Street Zen upgraded shares of Enlivex Therapeutics (NASDAQ:ENLV – Free Report) from a strong sell rating to a hold rating in a report issued on Saturday morning.
Several other brokerages have also recently commented on ENLV. D Boral Capital cut shares of Enlivex Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enlivex Therapeutics in a report on Monday, December 29th. HC Wainwright raised their target price on shares of Enlivex Therapeutics from $7.00 to $13.00 and gave the stock a “buy” rating in a report on Monday, January 12th. Finally, D. Boral Capital restated a “hold” rating on shares of Enlivex Therapeutics in a report on Monday, November 24th. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $13.00.
Enlivex Therapeutics Price Performance
Shares of NASDAQ:ENLV opened at $0.94 on Friday. Enlivex Therapeutics has a 12 month low of $0.66 and a 12 month high of $2.10. The stock has a market cap of $223.14 million, a price-to-earnings ratio of -1.71 and a beta of 1.52. The stock’s 50 day moving average price is $0.91 and its 200 day moving average price is $1.07.
Enlivex Therapeutics (NASDAQ:ENLV – Get Free Report) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.03. On average, sell-side analysts expect that Enlivex Therapeutics will post -0.7 EPS for the current year.
Institutional Investors Weigh In On Enlivex Therapeutics
A number of institutional investors have recently bought and sold shares of the business. Jane Street Group LLC increased its holdings in shares of Enlivex Therapeutics by 527.4% in the 1st quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock valued at $78,000 after purchasing an additional 67,886 shares during the period. Susquehanna International Group LLP purchased a new position in Enlivex Therapeutics during the third quarter valued at approximately $57,000. Finally, Citizens Financial Group Inc. RI purchased a new position in Enlivex Therapeutics during the third quarter valued at approximately $241,000. 1.02% of the stock is currently owned by institutional investors and hedge funds.
Enlivex Therapeutics Company Profile
Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.
The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.